Survey on prescription of the new laxatives in patients with chronic constipation under daily clinical practice, using real-world data - Survey on prescription of the new laxatives in the patients with chronic constipation

ELO discontinuation (DC) rate within 360 days was 78.7%. Inpatients, end-stage renal failure, and diagnosis of constipation by obstetrics/gynecology or oncology departments were identified as risks for DC. Diagnosis of constipation, diabetes mellitus, Parkinson's disease, or use of laxative (LX) was lower risk of DC. The prescription rate of stimulants and saline LX decreased and nearly half of them discontinued these LX within 360 days. Results of M4000E were published in JPT 52(3) 253-67 in Japanese.